Navigation Links
Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
Date:8/14/2008

CRANBURY, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) announced today the completion of a Phase 2a clinical trial of PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of heart failure (HF). The Phase 2a trial was a randomized, double-blind, placebo-controlled, single ascending dose study in 21 volunteers with controlled hypertension who received the medication or placebo subcutaneously. The purpose of the study was to demonstrate that PL-3994 can be given safely to patients taking antihypertensive medications commonly administered to heart failure and hypertension patients. The evaluations included safety, tolerability, pharmacokinetics and several pharmacodynamic endpoints, including levels of cyclic guanosine monophosphate (cGMP), a natural messenger nucleotide.

Dosing concluded with the successful achievement of the primary endpoint of the study, a pre-specified reduction in systemic blood pressure. No volunteer experienced a serious or severe adverse event. Elevations in plasma cGMP levels were all observed for several hours after single subcutaneous doses. Additional data analysis is ongoing and will be submitted for presentation when the analysis is complete.

"We are excited to confirm that PL-3994 can be given safely to patients who are taking blood pressure medications," stated Dr. Trevor Hallam, Palatin's Executive Vice President for Research and Development. "As we proceed with an additional Phase 2 study later this year, we will focus on the heart failure patients most in need of new therapies."

The previously announced Phase 1 study demonstrated that PL-3994 can be given safely and leads to a dose-related decrease i
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Unraveling life’s ... together. The Archer Family purchased a DNA ... DNA, but ended up with a lifetime of memories, ... within the family members’ DNA genuinely brought the family ... to search deeper into genetic history and prior to ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... , , ... issue of the journal,Diabetic Hypoglycemia ( http://www.hypodiab.com ) reviews ... Professor Vincent Marks , a leading ... criminal behavior, discusses how,hypoglycemia-related neuroglycopenia can cause behavioral changes, which ...
... ... the company as a regulatory consultant after retiring from Eli Lilly & Co. ... science and human pharmaceutical products, including director of regulatory affairs and clinical research. ... US regulatory submissions. , ...
... ... ... 2010 -- Agriculture is a game-changer that addresses multiple global issues – hunger, poverty, ... CEO Ellen Kullman told attendees of the 40th World Economic Forum Annual ...
Cached Biology Technology:Hypoglycemia - A Role in Criminal Behavior and a Consideration for Custodial Care 2Hypoglycemia - A Role in Criminal Behavior and a Consideration for Custodial Care 3Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant 2DuPont Chair and CEO: Agriculture is Key to Global Economic Growth, Sustainability and Security 2
(Date:7/11/2014)... 2014---A team of researchers from The Chinese University of ... gene of wild soybean linked to salt tolerance, with ... saline soil. This study published online in Nature ... genomic information for crop improvement. , Soybean is an ... human selection, cultivated soybeans have less genetic diversities than ...
(Date:7/11/2014)... animals often develop relationships with other group members to ... wild chacma baboons the strategy for grooming activities shows ... just published in the scientific journal Biology Letters ... baboons is not practiced without ulterior motives. To be ... the individual, while grooming another individual can provide access ...
(Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
... at the Stanford University School of Medicine have taken ... cells that could eventually be transplanted into living organisms. ... surgical resident Oscar Abilez, MD, and colleagues have successfully ... building blocks of blood vessels, after placing them in ...
... over a decade, the technique of distraction has been ... to reduce pain associated with certain medical procedures. The ... there is an important psychological element in the perception ... the harmful stimulus affecting the perception of the pain. ...
... of York have made a huge leap forward in the ... the Department of Biology has made a significant advance in ... biological warfare. , Bacteria like E. coli frequently try to ... called colicins, which are potent toxins. , The research ...
Cached Biology News:Stanford doctors advance in bid to turn mice stem cells into blood vessels 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 3Virtual realities against pain 2